232 related articles for article (PubMed ID: 17096348)
1. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
[TBL] [Abstract][Full Text] [Related]
2. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector.
Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Iezzi M; Cavallo F; Musiani P; Forni G; Monaci P
Int J Cancer; 2005 Jan; 113(1):67-77. PubMed ID: 15386429
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
[TBL] [Abstract][Full Text] [Related]
4. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
5. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
[TBL] [Abstract][Full Text] [Related]
6. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
[TBL] [Abstract][Full Text] [Related]
7. Gene-specific inhibition of breast carcinoma in BALB-neuT mice by active immunization with rat Neu or human ErbB receptors.
Masuelli L; Focaccetti C; Cereda V; Lista F; Vitolo D; Trono P; Gallo P; Amici A; Monaci P; Mattei M; Modesti M; Forni G; Kraus MH; Muraro R; Modesti A; Bei R
Int J Oncol; 2007 Feb; 30(2):381-92. PubMed ID: 17203220
[TBL] [Abstract][Full Text] [Related]
8. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
[TBL] [Abstract][Full Text] [Related]
9. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
[TBL] [Abstract][Full Text] [Related]
10. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors.
Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T
Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974
[TBL] [Abstract][Full Text] [Related]
11. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R
Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378
[TBL] [Abstract][Full Text] [Related]
12. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
13. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
14. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy.
Cipriani B; Fridman A; Bendtsen C; Dharmapuri S; Mennuni C; Pak I; Mesiti G; Forni G; Monaci P; Bagchi A; Ciliberto G; La Monica N; Scarselli E
Hum Gene Ther; 2008 Jul; 19(7):670-80. PubMed ID: 18533895
[TBL] [Abstract][Full Text] [Related]
16. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
17. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
18. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice.
Rovero S; Boggio K; Di Carlo E; Amici A; Quaglino E; Porcedda P; Musiani P; Forni G
Gene Ther; 2001 Mar; 8(6):447-52. PubMed ID: 11313823
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.
Aurisicchio L; Peruzzi D; Conforti A; Dharmapuri S; Biondo A; Giampaoli S; Fridman A; Bagchi A; Winkelmann CT; Gibson R; Kandimalla ER; Agrawal S; Ciliberto G; La Monica N
Clin Cancer Res; 2009 Mar; 15(5):1575-84. PubMed ID: 19240169
[TBL] [Abstract][Full Text] [Related]
20. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice.
Cappello P; Triebel F; Iezzi M; Caorsi C; Quaglino E; Lollini PL; Amici A; Di Carlo E; Musiani P; Giovarelli M; Forni G
Cancer Res; 2003 May; 63(10):2518-25. PubMed ID: 12750275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]